{
  "erlotinib": {
    "brand_names": [
      "Tarceva"
    ],
    "nda_number": "021743",
    "fda_approval_date": "2004-11-18",
    "targets": [
      "EGFR"
    ],
    "biomarkers": [
      "EGFR mutations"
    ],
    "indications": [
      "Non-small cell lung cancer"
    ],
    "fda_approved": true,
    "class": "EGFR Tyrosine Kinase Inhibitor",
    "mechanism_of_action": "Reversibly inhibits EGFR tyrosine kinase",
    "companion_diagnostics": [],
    "resistance_mutations": [
      "T790M"
    ],
    "combination_partner": null,
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958170",
    "confidence_level": "FDA_VERIFIED"
  },
  "osimertinib": {
    "brand_names": [
      "Tagrisso"
    ],
    "nda_number": "208065",
    "fda_approval_date": "2015-11-13",
    "targets": [
      "EGFR",
      "EGFR T790M"
    ],
    "biomarkers": [
      "EGFR exon 19 deletion",
      "EGFR L858R",
      "EGFR T790M"
    ],
    "indications": [
      "EGFR-mutated NSCLC",
      "T790M resistance NSCLC"
    ],
    "fda_approved": true,
    "class": "EGFR Tyrosine Kinase Inhibitor",
    "mechanism_of_action": "Irreversibly inhibits EGFR and T790M mutant",
    "companion_diagnostics": [],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [
      "Breakthrough Therapy"
    ],
    "clinical_evidence": {
      "breakthrough_therapy": true,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s014lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958191",
    "confidence_level": "FDA_VERIFIED"
  },
  "sotorasib": {
    "brand_names": [
      "Lumakras"
    ],
    "nda_number": "214665",
    "fda_approval_date": "2021-05-28",
    "targets": [
      "KRAS G12C"
    ],
    "biomarkers": [
      "KRAS G12C mutation"
    ],
    "indications": [
      "KRAS G12C mutated locally advanced or metastatic NSCLC"
    ],
    "fda_approved": true,
    "class": "KRAS Inhibitor",
    "mechanism_of_action": "Covalently binds KRAS G12C in GDP-bound state",
    "companion_diagnostics": [],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [
      "Accelerated Approval",
      "First-in-Class"
    ],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": true,
      "first_in_class": "First KRAS inhibitor",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958205",
    "confidence_level": "FDA_VERIFIED"
  },
  "adagrasib": {
    "brand_names": [
      "Krazati"
    ],
    "nda_number": "215400",
    "fda_approval_date": "2022-12-12",
    "targets": [
      "KRAS G12C"
    ],
    "biomarkers": [
      "KRAS G12C mutation"
    ],
    "indications": [
      "KRAS G12C mutated locally advanced or metastatic NSCLC",
      "KRAS G12C mutated colorectal cancer"
    ],
    "fda_approved": true,
    "class": "KRAS Inhibitor",
    "mechanism_of_action": "Covalently binds KRAS G12C, locks in inactive state",
    "companion_diagnostics": [],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [
      "Accelerated Approval"
    ],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": true,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215400s000lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958216",
    "confidence_level": "FDA_VERIFIED"
  },
  "olaparib": {
    "brand_names": [
      "Lynparza"
    ],
    "nda_number": "206162",
    "fda_approval_date": "2014-12-19",
    "targets": [
      "BRCA1",
      "BRCA2",
      "HRD"
    ],
    "biomarkers": [
      "germline BRCA mutations",
      "HRD-positive"
    ],
    "indications": [
      "BRCA-mutated advanced ovarian cancer",
      "BRCA-mutated HER2-negative metastatic breast cancer",
      "BRCA-mutated metastatic pancreatic cancer",
      "BRCA-mutated metastatic castration-resistant prostate cancer"
    ],
    "fda_approved": true,
    "class": "PARP Inhibitor",
    "mechanism_of_action": "Inhibits PARP1/2, exploits homologous recombination deficiency",
    "companion_diagnostics": [
      "BRACAnalysis CDx",
      "FoundationFocus CDxBRCA"
    ],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [
      "First-in-Class"
    ],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "First PARP inhibitor",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206162s039lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958226",
    "confidence_level": "FDA_VERIFIED"
  },
  "talazoparib": {
    "brand_names": [
      "Talzenna"
    ],
    "nda_number": "211651",
    "fda_approval_date": "2018-10-16",
    "targets": [
      "BRCA1",
      "BRCA2"
    ],
    "biomarkers": [
      "germline BRCA1 mutations",
      "germline BRCA2 mutations"
    ],
    "indications": [
      "BRCA-mutated HER2-negative locally advanced or metastatic breast cancer"
    ],
    "fda_approved": true,
    "class": "PARP Inhibitor",
    "mechanism_of_action": "PARP trapping, prevents DNA repair in BRCA-deficient cells",
    "companion_diagnostics": [
      "BRACAnalysis CDx"
    ],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958236",
    "confidence_level": "FDA_VERIFIED"
  },
  "alpelisib": {
    "brand_names": [
      "Piqray"
    ],
    "nda_number": "212526",
    "fda_approval_date": "2019-05-24",
    "targets": [
      "PIK3CA"
    ],
    "biomarkers": [
      "PIK3CA mutations"
    ],
    "indications": [
      "PIK3CA-mutated, hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer"
    ],
    "fda_approved": true,
    "class": "PI3K Inhibitor",
    "mechanism_of_action": "Selectively inhibits PI3K\u03b1 isoform",
    "companion_diagnostics": [
      "therascreen PIK3CA RGQ PCR Kit"
    ],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958246",
    "confidence_level": "FDA_VERIFIED"
  },
  "vemurafenib": {
    "brand_names": [
      "Zelboraf"
    ],
    "nda_number": "202429",
    "fda_approval_date": "2011-08-17",
    "targets": [
      "BRAF V600E"
    ],
    "biomarkers": [
      "BRAF V600E mutation"
    ],
    "indications": [
      "BRAF V600E mutation-positive unresectable or metastatic melanoma"
    ],
    "fda_approved": true,
    "class": "BRAF Inhibitor",
    "mechanism_of_action": "Inhibits mutant BRAF V600E kinase activity",
    "companion_diagnostics": [
      "cobas 4800 BRAF V600 Mutation Test"
    ],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958254",
    "confidence_level": "FDA_VERIFIED"
  },
  "dabrafenib": {
    "brand_names": [
      "Tafinlar"
    ],
    "nda_number": "202806",
    "fda_approval_date": "2013-05-29",
    "targets": [
      "BRAF V600E",
      "BRAF V600K"
    ],
    "biomarkers": [
      "BRAF V600E mutation",
      "BRAF V600K mutation"
    ],
    "indications": [
      "BRAF V600E mutation-positive unresectable or metastatic melanoma",
      "BRAF V600E mutation-positive metastatic NSCLC",
      "BRAF V600E mutation-positive anaplastic thyroid cancer"
    ],
    "fda_approved": true,
    "class": "BRAF Inhibitor",
    "mechanism_of_action": "Selective BRAF kinase inhibitor",
    "companion_diagnostics": [],
    "resistance_mutations": [],
    "combination_partner": "trametinib",
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202806s012lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958263",
    "confidence_level": "FDA_VERIFIED"
  },
  "crizotinib": {
    "brand_names": [
      "Xalkori"
    ],
    "nda_number": "202570",
    "fda_approval_date": "2011-08-26",
    "targets": [
      "ALK",
      "ROS1",
      "MET"
    ],
    "biomarkers": [
      "ALK rearrangements",
      "ROS1 rearrangements"
    ],
    "indications": [
      "ALK-positive metastatic NSCLC",
      "ROS1-positive metastatic NSCLC"
    ],
    "fda_approved": true,
    "class": "ALK Inhibitor",
    "mechanism_of_action": "Multi-kinase inhibitor targeting ALK, ROS1, MET",
    "companion_diagnostics": [
      "Vysis ALK Break Apart FISH Probe Kit",
      "VENTANA ALK (D5F3) CDx Assay"
    ],
    "resistance_mutations": [],
    "combination_partner": null,
    "special_designations": [],
    "clinical_evidence": {
      "breakthrough_therapy": false,
      "accelerated_approval": false,
      "first_in_class": "",
      "fda_label_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202570s018lbl.pdf"
    },
    "data_source": "FDA_Orange_Book_and_Labels",
    "verification_date": "2025-07-28T23:11:35.958272",
    "confidence_level": "FDA_VERIFIED"
  }
}